MELBOURNE, AUSTRALIA--(Marketwire - July 09, 2008) - Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT) today announced the publication of key research findings with its lead Alzheimer's Disease drug, PBT2. The article titled "Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxyquinoline analogs is associated with decreased interstitial Abeta" appears in the current edition of the prestigious scientific journal Neuron, and can be viewed online.
